CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

daunorubicin and cytarabine

Last Updated: March 9, 2021
Result type: Reports
Project Number: PC0237-000
Product Line: Reimbursement Review

Generic Name: daunorubicin and cytarabine

Brand Name: Vyxeos

Manufacturer: Jazz Pharmaceuticals Canada Inc.

Therapeutic Area: Acute myeloid leukemia

Indications: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Manufacturer Requested Reimbursement Criteria1: For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Submission Type: Initial

Tumour Type: Leukemia

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 17, 2020
Call for patient/clinician input closedFebruary 12, 2021
Clarification:

- Patient input submission received from The Leukemia & Lymphoma Society of Canada

Submission receivedJanuary 22, 2021
Submission acceptedFebruary 05, 2021
Review initiatedFebruary 08, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 23, 2021
Deadline for sponsors commentsMay 04, 2021
CADTH responses on draft review report(s) provided to sponsorMay 31, 2021
Expert committee meeting (initial)June 10, 2021
Draft recommendation issued to sponsorJune 22, 2021
To
June 24, 2021
Draft recommendation posted for stakeholder feedback-